Sol-Gel Technologies Ltd. Logo

Sol-Gel Technologies Ltd.

Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.

SLGL | US

Overview

Corporate Details

ISIN(s):
IL0011417206
LEI:
Country:
United States of America
Address:
7 GOLDA MEIR ST., 7403648 NESS ZIONA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sol-Gel Technologies Ltd. is a dermatology company engaged in the identification, development, and commercialization of topical drug products. The company has developed FDA-approved treatments, including Twyneo® for acne vulgaris and Epsolay® for inflammatory lesions of rosacea. Its clinical-stage pipeline focuses on delivering innovative treatments for rare skin conditions, with a lead candidate, patidegib gel, designed to prevent new basal cell carcinoma lesions in patients with Gorlin syndrome. Sol-Gel aims to address unmet patient needs by developing novel formulations that surpass the current standard of care in medical dermatology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sol-Gel Technologies Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sol-Gel Technologies Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sol-Gel Technologies Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America CARM
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America CPRX
cbdMD, Inc. Logo
Produces & distributes lab-tested CBD wellness products for people and pets.
United States of America YCBD
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920

Talk to a Data Expert

Have a question? We'll get back to you promptly.